Effect of Ca++ and Somatostatin on Insulin Release in Humans

M. Lunetta,R. Leonardi,S. Leotta,S. Rapisarda,L. Mughini
DOI: https://doi.org/10.1055/s-2007-1018754
1983-09-01
Abstract:It has been shown that somatostatin (SRIF) is an inhibitor of many polipeptide hormones including insulin (Alberti, Christensen, Christensen, Hansen, Iversen, Lundbaek and Orsskov 1974) and that the inhibition on glucose-induced insulin release in vitro can be overcome by increasing Ca ++ concentration in the perfusate medium (Curry and Bennett 1974). The aim of our study was to evaluate whether an increase in Ca ++ plasma concentration could remove the inhibitory effect of SRIF also in humans
What problem does this paper attempt to address?